Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLK3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PLK3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PLK3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLK3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PLK3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004277016 | Thyroid | ATC | signal transduction in response to DNA damage | 90/6293 | 172/18723 | 3.01e-07 | 4.52e-06 | 90 |
GO:003629425 | Thyroid | ATC | cellular response to decreased oxygen levels | 85/6293 | 161/18723 | 3.86e-07 | 5.65e-06 | 85 |
GO:000008216 | Thyroid | ATC | G1/S transition of mitotic cell cycle | 107/6293 | 214/18723 | 4.83e-07 | 6.99e-06 | 107 |
GO:003033033 | Thyroid | ATC | DNA damage response, signal transduction by p53 class mediator | 45/6293 | 72/18723 | 4.87e-07 | 7.03e-06 | 45 |
GO:000709312 | Thyroid | ATC | mitotic cell cycle checkpoint | 69/6293 | 129/18723 | 2.52e-06 | 2.96e-05 | 69 |
GO:007145624 | Thyroid | ATC | cellular response to hypoxia | 78/6293 | 151/18723 | 3.44e-06 | 3.86e-05 | 78 |
GO:000008612 | Thyroid | ATC | G2/M transition of mitotic cell cycle | 72/6293 | 137/18723 | 3.61e-06 | 4.03e-05 | 72 |
GO:000007513 | Thyroid | ATC | cell cycle checkpoint | 84/6293 | 169/18723 | 1.05e-05 | 1.04e-04 | 84 |
GO:000703015 | Thyroid | ATC | Golgi organization | 79/6293 | 157/18723 | 1.07e-05 | 1.05e-04 | 79 |
GO:001094813 | Thyroid | ATC | negative regulation of cell cycle process | 134/6293 | 294/18723 | 1.19e-05 | 1.15e-04 | 134 |
GO:004483912 | Thyroid | ATC | cell cycle G2/M phase transition | 75/6293 | 148/18723 | 1.28e-05 | 1.24e-04 | 75 |
GO:190198813 | Thyroid | ATC | negative regulation of cell cycle phase transition | 116/6293 | 249/18723 | 1.33e-05 | 1.27e-04 | 116 |
GO:003112215 | Thyroid | ATC | cytoplasmic microtubule organization | 34/6293 | 56/18723 | 2.92e-05 | 2.45e-04 | 34 |
GO:000697016 | Thyroid | ATC | response to osmotic stress | 45/6293 | 84/18723 | 1.27e-04 | 9.03e-04 | 45 |
GO:190280615 | Thyroid | ATC | regulation of cell cycle G1/S phase transition | 79/6293 | 168/18723 | 2.04e-04 | 1.35e-03 | 79 |
GO:200004522 | Thyroid | ATC | regulation of G1/S transition of mitotic cell cycle | 68/6293 | 142/18723 | 2.86e-04 | 1.82e-03 | 68 |
GO:003246511 | Thyroid | ATC | regulation of cytokinesis | 47/6293 | 92/18723 | 3.95e-04 | 2.39e-03 | 47 |
GO:00513027 | Thyroid | ATC | regulation of cell division | 80/6293 | 177/18723 | 8.54e-04 | 4.68e-03 | 80 |
GO:006168431 | Thyroid | ATC | chaperone-mediated autophagy | 12/6293 | 16/18723 | 8.59e-04 | 4.68e-03 | 12 |
GO:004477313 | Thyroid | ATC | mitotic DNA damage checkpoint | 40/6293 | 81/18723 | 2.36e-03 | 1.10e-02 | 40 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLK3 | SNV | Missense_Mutation | | c.1585N>A | p.Leu529Met | p.L529M | Q9H4B4 | protein_coding | tolerated(0.51) | possibly_damaging(0.516) | TCGA-AR-A24M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
PLK3 | SNV | Missense_Mutation | | c.1166C>T | p.Ala389Val | p.A389V | Q9H4B4 | protein_coding | tolerated(0.35) | benign(0.001) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
PLK3 | insertion | In_Frame_Ins | novel | c.432_433insCGCCGAGCAGGGCGTGGGCACTTGACCCCC | p.Arg144_Lys145insArgArgAlaGlyArgGlyHisLeuThrPro | p.R144_K145insRRAGRGHLTP | Q9H4B4 | protein_coding | | | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PLK3 | insertion | Frame_Shift_Ins | novel | c.530_531insAATCCAGGCAGCG | p.His177GlnfsTer23 | p.H177Qfs*23 | Q9H4B4 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLK3 | SNV | Missense_Mutation | novel | c.1543T>C | p.Ser515Pro | p.S515P | Q9H4B4 | protein_coding | tolerated(0.1) | possibly_damaging(0.53) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PLK3 | SNV | Missense_Mutation | | c.512N>T | p.Ser171Phe | p.S171F | Q9H4B4 | protein_coding | deleterious(0) | possibly_damaging(0.506) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PLK3 | SNV | Missense_Mutation | rs755159184 | c.929N>A | p.Arg310His | p.R310H | Q9H4B4 | protein_coding | tolerated(0.09) | benign(0.227) | TCGA-ZJ-AAXD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PLK3 | insertion | In_Frame_Ins | novel | c.1910_1911insTACCTG | p.Leu637_Arg638insThrTrp | p.L637_R638insTW | Q9H4B4 | protein_coding | | | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
PLK3 | SNV | Missense_Mutation | novel | c.952N>C | p.Tyr318His | p.Y318H | Q9H4B4 | protein_coding | tolerated(0.05) | possibly_damaging(0.811) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLK3 | deletion | Frame_Shift_Del | | c.1006delN | p.Asn338ThrfsTer35 | p.N338Tfs*35 | Q9H4B4 | protein_coding | | | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | TAE-684 | TAE-684 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 178102294 | BI-2536 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | RG-1530 | RG-1530 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GW843682X | GW843682X | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | WORTMANNIN | WORTMANNIN | 17135248 |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | LINIFANIB | LINIFANIB | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GS 6201 | GS 6201 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | PHA-767491 | CHEMBL225519 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565601 | ONVANSERTIB | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GNF-PF-2301 | CHEMBL578061 | |